Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Celcuity, Inc. CELC

Healthcare  —  Biotechnology
79.52 0.15 0.19% as of 25 Sep
Market cap
$3.9B
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Celcuity, Inc. (CELC) Business Profile

Updated before January 2025

Company Overview

Celcuity, Inc. (NASDAQ: CELC) is a biotechnology company dedicated to advancing personalized medicine through innovative diagnostic and therapeutic solutions. Founded in 2012 by Brian Sullivan and Lance Laing, the company is headquartered in Minneapolis, Minnesota. Celcuity’s mission is to transform the way cancer is diagnosed and treated by leveraging its proprietary cellular analysis technology. The company is led by a team of seasoned professionals, including Brian Sullivan, who serves as the Chairman and CEO, and Lance Laing, the Chief Science Officer. Their combined expertise in biotechnology and business strategy has positioned Celcuity as a leader in the precision medicine space.

Core Business Segments

Diagnostic Solutions

Celcuity’s primary focus is on developing diagnostic tests that identify the molecular and cellular mechanisms driving cancer. The company’s flagship product is the CELsignia platform, a proprietary diagnostic technology that analyzes live patient tumor cells to uncover dysregulated cellular pathways. This platform enables oncologists to select the most effective therapies for their patients, improving treatment outcomes and reducing unnecessary side effects.

Therapeutic Development

In addition to diagnostics, Celcuity is actively involved in the development of targeted therapies. The company collaborates with pharmaceutical partners to identify and validate new drug targets, leveraging its cellular analysis expertise. This dual focus on diagnostics and therapeutics allows Celcuity to address unmet medical needs in oncology comprehensively.

Research Services

Celcuity also offers research services to pharmaceutical and biotechnology companies. These services include pathway analysis, drug response profiling, and biomarker discovery. By providing actionable insights into cellular behavior, Celcuity helps its partners accelerate drug development and improve clinical trial success rates.

Business Model

Celcuity operates at the intersection of diagnostics and therapeutics, creating a unique business model that integrates cutting-edge technology with clinical applications. The company generates revenue through multiple streams, including:

  1. Diagnostic Test Sales: Revenue from the sale of CELsignia tests to healthcare providers and laboratories.
  2. Collaborative Partnerships: Licensing agreements and milestone payments from pharmaceutical partners.
  3. Research Services: Fees for custom cellular analysis and biomarker discovery projects.

This diversified revenue model ensures financial stability while supporting Celcuity’s mission to advance personalized medicine.

Strategic Direction

Celcuity is committed to expanding its diagnostic and therapeutic offerings to address a broader range of cancers and other diseases. Key strategic initiatives include:

  1. Pipeline Expansion: Developing new diagnostic tests for additional cancer types, such as lung and colorectal cancer.
  2. Therapeutic Collaborations: Partnering with leading pharmaceutical companies to co-develop targeted therapies.
  3. Global Reach: Expanding its presence in international markets through strategic partnerships and regulatory approvals.
  4. Sustainability Goals: Implementing environmentally friendly practices in its operations and supply chain.

By focusing on innovation and collaboration, Celcuity aims to solidify its position as a leader in precision medicine.

Competitive Landscape

Celcuity operates in a highly competitive market, facing competition from both established players and emerging startups. Key competitors include:

  1. Foundation Medicine: A leader in genomic profiling and companion diagnostics.
  2. Guardant Health: Specializes in liquid biopsy tests for cancer detection and monitoring.
  3. Caris Life Sciences: Offers comprehensive molecular profiling services.
  4. NanoString Technologies: Focuses on gene expression analysis and biomarker discovery.

Despite the competition, Celcuity differentiates itself through its unique cellular analysis technology and dual focus on diagnostics and therapeutics.

Risk Factors

Like any biotechnology company, Celcuity faces several risks that could impact its operations and financial performance:

  1. Regulatory Challenges: Delays in obtaining FDA or international regulatory approvals for new products.
  2. Market Dependence: Reliance on the adoption of CELsignia tests by healthcare providers.
  3. Supply Chain Disruptions: Potential delays in the production and distribution of diagnostic kits.
  4. Competitive Pressure: The risk of losing market share to competitors with similar or superior technologies.
  5. Financial Risks: Dependence on external funding to support research and development activities.

Recent Developments

Celcuity has made significant strides in recent years, including:

  1. FDA Approval: Securing regulatory approval for the CELsignia HER2 Pathway Activity Test, a groundbreaking diagnostic tool for breast cancer.
  2. Partnerships: Collaborating with leading pharmaceutical companies to co-develop targeted therapies.
  3. Clinical Trials: Initiating multiple clinical trials to validate the efficacy of its diagnostic tests and therapeutic candidates.
  4. Technological Advancements: Enhancing the CELsignia platform with new features and capabilities.

These developments underscore Celcuity’s commitment to innovation and patient-centric care.

Investment Considerations

Strengths

  1. Innovative Technology: Proprietary cellular analysis platform with proven clinical utility.
  2. Diversified Revenue Streams: Multiple income sources, including diagnostics, therapeutics, and research services.
  3. Strong Leadership: Experienced management team with a track record of success.
  4. Market Potential: Growing demand for personalized medicine and targeted therapies.

Risks

  1. Regulatory Hurdles: Potential delays in product approvals.
  2. Competitive Market: Intense competition from established players and new entrants.
  3. Financial Dependence: Reliance on external funding for R&D activities.

Conclusion

Celcuity, Inc. is at the forefront of personalized medicine, offering innovative diagnostic and therapeutic solutions that address unmet medical needs. With a strong focus on innovation, collaboration, and patient outcomes, the company is well-positioned for long-term growth. However, investors should carefully consider the associated risks before making investment decisions. As Celcuity continues to expand its product portfolio and global reach, it remains a compelling player in the biotechnology sector.